Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Effector Therapeutics Inc (NQ: EFTR )

0.5192 -0.0515 (-9.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,199,463
Open 0.5814
Bid (Size) 0.5000 (11)
Ask (Size) 0.5074 (5)
Prev. Close 0.5707
Today's Range 0.5126 - 0.5970
52wk Range 0.3378 - 1.480
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
eFFECTOR Therapeutics Discloses Updated Data From Mid-Stage Breast Cancer Study
eFFECTOR Therapeutics Inc (NASDAQ: EFTR) announced new interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 study of zotatifin in patients with estrogen receptor positive... 
Via Benzinga
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+16.41%
+16.41%
1 Month
-9.86%
-9.86%
3 Month
-17.98%
-17.98%
6 Month
-58.46%
-58.46%
1 Year
+23.38%
+23.38%

More News

Read More
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
3 Promising Biotech Stocks That Will Make Early Investors Rich
Via InvestorPlace
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Stock To Rally Over 500%? Analyst Predict Blockbuster Status For Cancer Candidates
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
Via Benzinga
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.